ArticleCureus2026
Development of the Gutti Score: A Universal Clinical Assessment Framework for Patients Receiving Gabapentinoids, Opioids, Benzodiazepines, and Other Central Nervous System Depressants.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of gabapentinoids, opioids, benzodiazepines, and other central nervous system (CNS) depressants has increased significantly, raising concerns about respiratory depression and overdose risk, particularly when used in combination. Existing risk assessment tools primarily focus on opioids and do not comprehensively account for multiple medication classes and patient comorbidities.
objectiveTo develop and retrospectively apply a structured clinical framework ("Gutti Score") intended to organize medication-related and patient-specific factors associated with overdose risk among patients receiving gabapentinoids, opioids, benzodiazepines, and other central nervous system depressants.
methodsA retrospective observational pilot study was conducted using an existing patient database from 2017 to 2019. Patients prescribed gabapentinoids (gabapentin or pregabalin), opioids, benzodiazepines, or other CNS depressants were included. A structured scoring framework incorporating medication exposure and comorbid conditions was retrospectively applied using exploratory cumulative burden categories. Patients were followed for one year, and outcomes included overdose events and mortality.
resultsA total of 112 patients were included. Forty-six patients (41.1%) demonstrated lower cumulative burden profiles, while sixty-six patients (58.9%) demonstrated intermediate cumulative burden profiles. No overdose events or overdose-related deaths were observed during the follow-up period, limiting assessment of predictive performance. Patients within the intermediate cumulative burden category demonstrated a higher burden of comorbid conditions and greater medication exposure compared with those in the lower cumulative burden category.
conclusionThese findings support the feasibility of the proposed framework; however, no conclusions regarding predictive validity or discriminatory performance can be established from the present study. Further prospective investigation involving larger and more diverse populations is required before broader clinical applicability can be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.